NFS Capital provides biotech and life sciences equipment financing for clinical-stage, pre-commercial, and growing companies across the U.S. and Canada. We listen to the full story behind the request: what the equipment makes possible, the milestone or capacity need driving the purchase, the capital and contracts supporting the business, the vendors involved, and the timing required to bring the project online.
Biotech and life sciences companies with operating history, institutional or sponsor support, grants, contracts, committed capital, or other meaningful strengths can bring us requests ranging from a single high-value instrument to larger, multi-vendor and phased equipment projects.
Biotech and clinical-stage equipment financing helps life sciences companies acquire laboratory, analytical, bioprocessing, automation, and production equipment needed to move from one business or scientific milestone to the next without relying solely on conventional bank criteria.
These transactions can involve a single high-value system or a larger project with several vendors, deposits, delivery dates, installation steps, and equipment schedules. The equipment may be essential to commercialization, production scale-up, testing capacity, customer commitments, or a new operating capability long before the full economic benefit is visible in historical financial statements.
NFS Capital evaluates the equipment, business purpose, project timing, operating history, financial profile, contracts, committed capital, sponsor or institutional support, and the broader financing context.
NFS Capital is a fit for operating and clinical-stage life sciences companies that need business-critical equipment and have a financing request that benefits from judgment, structure, and context.
We work with companies that are:
Clinical-stage or pre-commercial businesses acquiring equipment needed to reach a development, testing, production, or commercialization milestone
Life sciences manufacturers expanding regulated production capacity, including cell therapy, bioprocessing, fill-finish, or related manufacturing operations
Diagnostics and clinical laboratory companies adding analyzers, sequencers, automation, or testing platforms
Medtech businesses financing manufacturing equipment or equipment supporting contracted customer deployments
University spinoffs and research commercialization companies moving from grant-supported research toward commercial operations
Purchasing equipment from multiple vendors or managing phased delivery, installation, or validation timelines
Using grants, committed capital, contracts, institutional backing, sponsor support, or other meaningful strengths to support the business plan
Seeking financing of at least $150,000, with many biotech and life sciences opportunities falling in the $500,000–$5 million range
NFS Capital is generally not a fit for consumer purchases, small-ticket equipment requests below our transaction profile, or very early concept-stage requests without meaningful business support, a clear equipment need, or a credible path to operating use.
Laboratory equipment financing may involve a single high-value instrument or a broader package of analytical, automation, bioprocessing, and production systems. NFS Capital finances business-critical equipment across these categories, including:
Next-generation sequencers, including Illumina, PacBio, and Oxford Nanopore systems: typically $500K to $1M+
Mass spectrometers and liquid chromatography systems: typically $200K to $800K
Flow cytometers and cell sorters: typically $200K to $600K
Bioreactors and bioprocessing systems: typically $300K to $2M+
Cell therapy manufacturing equipment and fill-finish systems: typically $500K to $5M
Cleanroom equipment and regulated production infrastructure: typically $750K to $5M+
Cryogenic storage and ultra-low-temperature systems: typically $100K to $500K
Automated liquid handling and high-throughput screening platforms: typically $300K to $1M
Electron microscopes and advanced imaging systems: typically $500K to $2M
Robotic laboratory automation systems: typically $300K to $1.5M
High-throughput clinical PCR and qPCR systems: typically $100K to $500K
Equipment and project costs vary by manufacturer, configuration, software, accessories, installation, service requirements, and project scope.
Life sciences companies often need equipment at the exact point when the business is changing fastest. We finance situations including:
Equipment needed to reach a clinical, validation, production, or commercialization milestone
Production scale-up for regulated life sciences manufacturing, cell therapy, bioprocessing, diagnostics, or other life sciences operations
Capacity expansion tied to customer demand, contracts, recurring revenue, or a growing testing pipeline
Laboratory automation projects designed to increase throughput, consistency, or testing capacity
New laboratory, diagnostics, or production sites requiring several systems to come online together
Multi-vendor or phased equipment projects with different deposit, delivery, installation, or validation schedules
Equipment purchases required before the resulting growth is fully visible in historical financials
Prior bank decline or limited bank availability despite a credible business case for the equipment
What connects these situations is not a perfect credit profile. It is a business-critical equipment need with a credible operating purpose, meaningful support behind the company, and a financing request that deserves a closer review.
A clinical-stage company’s financial statements are backward-looking by design. The equipment decision is forward-looking. A sequencer may be needed to take on testing volume that is not yet reflected in trailing revenue. A bioprocessing system may be required to move from development into larger-scale production. A laboratory automation platform may be the missing piece that makes a contracted workflow scalable.
That timing mismatch creates a financing challenge conventional credit models do not always handle well. Life sciences projects may depend on institutional capital, grants, signed customer agreements, multiple vendor deposits, long equipment lead times, installation or validation steps, and staged purchases. Waiting until the benefit is obvious in historical financials can mean waiting until after the opportunity has passed.
NFS Capital evaluates the operating case around the equipment. We look at why the system is needed, what milestone or capacity requirement it supports, how the project is funded, what other strengths support the business, and how vendor and delivery timing fit the broader plan. The goal is to structure financing when the equipment can make a difference, not only after the results are already in the rearview mirror.
The right structure depends on the equipment, transaction size, expected ownership period, business profile, vendor timing, project plan, and cash-flow objectives.
NFS Capital can consider:
Equipment Finance Agreements (EFAs) for companies that expect to own and use the equipment long term
Fair Market Value (FMV) leases for equipment that may be upgraded, replaced, or refreshed as technology changes
$1 buyout leases for businesses focused on long-term equipment ownership
Master Lease Agreements for companies planning multiple equipment acquisitions or schedules over time
Multi-draw or staged funding for projects with multiple vendors, deposits, delivery dates, or installation milestones
Sale-leaseback structures for qualifying equipment previously purchased with cash when the business wants to return capital to operations
Deferred, step-up, seasonal, or other payment structures when appropriate for the specific transaction
The right structure can help align the financing with the equipment purchase, project timeline, and broader business objective.
NFS Capital uses a straightforward process designed to help businesses understand whether their equipment financing request is a fit.
We review the equipment, transaction size, business need, vendor information, purchase orders or quotations, intended use of the equipment, delivery or installation timeline, and the milestone or operating objective behind the request.
Our team evaluates the company’s credit and financial profile together with operating history, management experience, contracts, customer demand, grant or institutional support, committed capital, equipment, and other supporting information: the full story behind the transaction, not just a narrow checklist.
After documentation and closing requirements are completed, NFS Capital coordinates funding with the customer, vendor, and related parties. For larger or phased projects, timing may reflect vendor deposits, equipment delivery, installation, documentation, and other transaction-specific milestones.
Biotech equipment purchases often sit at the intersection of science, capital planning, and timing. The system is needed because the business is moving forward, but the financial statements may still be catching up. NFS Capital’s experienced financing team evaluates the transaction in that broader context.
For biotech and life sciences equipment projects, NFS Capital provides:
Equipment financing for transactions starting at $150K and up to $20M+, with many biotech and life sciences opportunities in the $500K–$5M range
24–48 hour decisions when the information needed for review is available
Credit evaluation that can consider operating history, contracts, customer demand, grants, institutional or sponsor support, committed capital, and the business purpose behind the equipment
Multi-vendor, multi-asset, and staged funding structures for larger or phased projects
Experience with life sciences, healthcare, manufacturing, automation, technology, and other equipment-intensive sectors
A relationship-based approach focused on helping companies move forward with business-critical equipment projects
NFS Capital has been in business for 20+ years and has financed more than $2 billion in equipment transactions for companies throughout the U.S. and Canada.
A clinical genetics and genomic diagnostics laboratory needed to expand sequencing capacity with multiple Illumina NovaSeq X Plus systems. The request involved high-value analytical equipment and more than one equipment schedule, making the financing structure and acquisition timing important to the overall project.
NFS Capital financed the sequencing equipment under two schedules totaling $2,812,500, supporting the laboratory’s investment in additional next-generation sequencing capacity.
Source: NFS Capital closed transaction data. Company name and identifying details not disclosed.
Yes. Being pre-revenue does not automatically prevent a biotech company from being considered for equipment financing. NFS Capital evaluates the broader business context, including factors such as institutional backing, committed capital, grants, contracts, management experience, the equipment need, and how the company plans to support the equipment investment. The specific structure depends on the transaction, but limited revenue history is not by itself disqualifying.
NFS Capital can consider next-generation sequencers, mass spectrometers, liquid chromatography systems, flow cytometers, cell sorters, bioreactors, bioprocessing systems, cell therapy and fill-finish equipment, automated liquid handling platforms, high-throughput screening systems, cryogenic storage, electron microscopes, robotic laboratory automation, clinical-grade PCR and qPCR systems, and other business-critical laboratory or production equipment. NFS can finance a single major system or a broader multi-vendor project.
Not always. Personal guarantees depend on the specific borrower, ownership structure, transaction, equipment, and overall credit profile. This can be relevant for venture-backed or institutionally owned biotech companies where a traditional personal-guarantee structure may not fit the ownership model. NFS evaluates each request individually rather than applying the same guarantee requirement to every transaction.
NFS Capital finances equipment transactions starting at $150,000. Many biotech and life sciences opportunities fall within the $500,000–$5 million range, and NFS can consider larger transactions up to $20 million+ depending on the opportunity.
A multi-draw structure allows a larger equipment project to be funded in stages instead of requiring every piece of equipment to be purchased and funded at the same time. A biotech company may have laboratory automation, bioprocessing systems, cleanroom equipment, and analytical instruments arriving from different vendors on different schedules. Financing can be structured around agreed equipment orders, deposits, deliveries, or other project milestones as the transaction progresses.
Yes. Contracted customers, recurring revenue arrangements, facility agreements, or other commitments that help support the business case for an equipment investment can be considered as part of the overall financing evaluation. Contracts do not replace the full credit review, but they can provide useful context around demand, expected equipment utilization, and the commercial purpose of the transaction.
NFS Capital can often provide a decision in 24–48 hours when the information needed for review is available. Timing depends on transaction size, project complexity, vendors, documentation, and the overall structure. Final funding occurs after the required due diligence, documentation, and closing conditions are completed.
Available structures can include Equipment Finance Agreements, FMV leases, $1 buyout leases, Master Lease Agreements, multi-draw or staged funding, sale-leasebacks, and flexible payment schedules. The appropriate structure depends on the equipment, expected ownership period, project timing, cash-flow objectives, and the company’s broader financing needs.
If your biotech or life sciences company needs financing for sequencing, laboratory automation, bioprocessing, manufacturing equipment, or another business-critical project, NFS Capital can help you determine whether the transaction is a fit.
Start your financing request and connect with a team that understands clinical-stage growth, equipment timing, multi-vendor projects, and equipment financing requests starting at $150K.
